AMAshish Maheshwari

Ashish Maheshwari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ashish Maheshwari has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Machine Learning Models for Prediction of Response to Therapeutic Plasma Exchange in Pediatric Acute Liver Failure

    by Tamoghna Biswas, Varun Ramamohan, Tamal Majumder, Seema Alam, Vikrant Sood, Rajeev Khanna, Ashish Maheshwari, Meenu Bajpai, Bikrant B. Lal


  • Therapeutic plasma exchange provides native liver survival benefit in children with acute liver failure: A propensity score‐matched analysis

    by Tamoghna Biswas, Bikrant Bihari Lal, Vikrant Sood, Avalareddy Ashritha, Ashish Maheshwari, Meenu Bajpai, Guresh Kumar, Rajeev Khanna, Seema Alam

    Objectives: This study aimed to evaluate the safety and efficacy of therapeutic plasma exchange (TPE) in pediatric acute liver failure (PALF).Methods: All children aged 2‐18 years with PALF were included. The intervention cohort included a subset of PALF patients undergoing complete three sessions of TPE, whereas the matching controls were derived by propensity score matching from the patient cohort who did not receive any TPE. Propensity matching was performed based on the international normalized ratio (INR), grade of hepatic encephalopathy (HE), age, bilirubin, and ammonia levels. The primary outcome measure was native liver survival (NLS) in the two arms on day 28.Results: Of the total cohort of 403 patients with PALF, 65 patients who received TPE and 65 propensity‐matched controls were included in analysis. The 2 groups were well balanced with comparable baseline parameters. On day 4, patients in the TPE group had significantly lower INR (P = 0.001), lower bilirubin (P = 0.008), and higher mean arterial pressure (MAP) (P = 0.033) than controls. The NLS was 46.15% in the TPE arm and 26.15% in the control arm. The overall survival (OS) was 50.8% in the TPE arm and 35.4% in the control arm. Kaplan‐Meier survival analysis showed a significantly higher NLS in patients receiving TPE than controls (P = 0.001). On subgroup analysis, NLS benefit was predominantly seen in hepatitis A‐related and indeterminate PALF.Conclusion: TPE improved NLS and OS in a propensity‐matched cohort of patients with PALF. Patients receiving TPE had lower INR and bilirubin levels and higher MAP on day 4.


  • Large volume plasmapheresis using a single‐use immunoadsorption column: A cost‐effective approach for desensitization in ABO‐incompatible liver transplant

    by Sarika Agarwal, Ashish Maheshwari, Meenu Bajpai

    Introduction: Liver transplant is a life‐saving treatment, but due to the limited availability of suitable liver donors, ABO‐incompatible liver transplants (ABOi‐LT) are conducted to increase the availability of liver donors. Perioperative desensitization for ABOi‐LT is an established strategy to circumvent the risk of graft rejection. A single prolonged session can be performed to achieve the desired titers to avoid using multiple immunoadsorption (IA) columns or off‐label reuse of single‐use columns. This study retrospectively assessed the effectiveness of a single prolonged plasmapheresis session using IA as a desensitization strategy in live donor liver transplant (LDLT).Materials and methods: This retrospective observational study conducted at a center for liver diseases in North India on six ABOi‐LDLT patients who underwent single prolonged IA sessions in the perioperative period from January 2018 to June 2021.Results: Median baseline titer in patients was 320 (64, 1024). The median plasma volume adsorbed was 7.5 volumes (4, 8) per procedure, with a mean procedure time of 600 min (310‐753). The reduction in titer ranged from 4 log to 7 log reduction per procedure. Two patients developed transient hypotension during the procedure, which was managed successfully. The median duration of pre‐transplant hospital stay was 1.5 days (1, 3).Conclusion: Desensitization therapy helps overcome the ABO barrier and decreases the waiting period before a transplant when ABO identical donors are unavailable. A single prolonged IA session reduces the cost of additional IA columns and hospital stay, thus making it a cost‐effective approach to desensitization.


  • Open Access

    Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)

    by Meenu Bajpai, Ashish Maheshwari, Vikas Dogra, Suresh Kumar, Ekta Gupta, Pratibha Kale, Vandana Saluja, Sherin S Thomas, Nirupama Trehanpati, Chhagan Bihari, et al.

    Importance: No proven treatment is available for severely ill COVID-19. Therapeutic use of COVID-19 convalescent plasma (COPLA) is under investigation. Objective: To compare the efficacy of COPLA with standard medical therapy (SMT) alone in severe COVID-19 patients. Design, setting and participants: A multicentric, open-labelled, phase-III randomised controlled trial conducted at two treatment centres with COPLA collected at the third dedicated centre in North-India, the coordinating centre during trial from June 2020 to December 2020. The study population comprised 400 participants in the ratio of 1:1 in each treatment group. Intervention: One group received COPLA with SMT (n=200), and another group received SMT only (n=200). Main outcome measures: Primary outcome was time to clinical improvement measured by a two-point reduction in the ordinal scale. Secondary outcomes included duration of O 2 therapy, the proportion of patients on mechanical ventilation at day-7, mortality, SARS-CoV-2 antibody levels, cytokine levels and incidence of adverse events. Results: The median time to a two-point reduction in the ordinal scale in both groups was 9 days (IQR=7–13) (p=0.328). The median duration of O 2 therapy was 8 days (IQR=6–12) in COPLA and 10 days (IQR=6–12) in SMT group (p=0.64). The PaO 2 /FiO 2 ratio showed significant improvement at 7 days in COPLA group(p=0.036). There was no difference in mortality till 28 days in both groups (p=0.62). However, if COPLA was given within 3 days of hospital admission, a significant reduction in ordinal scale was observed (p=0.04). Neutralising antibody titres in COPLA group (80 (IQR 80–80)) were higher than SMT group (0 (IQR 0–80)) at 48 hours (p=0.001). COPLA therapy led to a significant reduction in TNF-α levels at 48 hours (p=0.048) and D-dimer at 7 days (p=0.02). Mild allergic reactions were observed in 3 (1.5%) patients in COPLA group. Conclusion and relevance: Convalescent plasma with adequate antibody titres should be transfused in COVID-19 patients along with SMT in the initial 3 days of hospitalisation for better clinical outcomes. Trial registration number: NCT04425915 .


  • Open Access

    Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients

    by Meenu Bajpai, Ashish Maheshwari, Suresh Kumar, Karan Chhabra, Pratibha Kale, Ashad Narayanan, Amita Gupta, Ekta Gupta, Nirupama Trehanpati, Reshu Agarwal, et al.

    Background: Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared efficacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients. Methods: One group received COPLA with standard medical care (n = 14), and another group received random donor FFP, as control with standard medical care (n = 15) in severe COVID-19 disease. Results: The proportion of patients free of ventilation at day seven were 78.5% in COPLA group, and 93.3 % in control group were not significant (p= 0.258). However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups.


  • Open Access

    Sustained expression of inflammatory monocytes and activated T cells in COVID‐19 patients and recovered convalescent plasma donors

    by Ravinder Singh, Hamed Hemati, Meenu Bajpai, Pushpa Yadav, Ashish Maheshwari, Suresh Kumar, Sonal Agrawal, Jayesh Kumar Sevak, Mojahidul Islam, Jaswinder Singh Mars, et al.

    Introduction: Intense monocyte activation and infiltration into the target tissues are the main mechanisms of lung injury in severe acute respiratory syndrome coronavirus 2 infection. A reduction in the degree and nature of such cellular responses is expected following recovery. We aimed to investigate the immune responses in moderate coronavirus disease 2019 (COVID‐19) patients and recovered patients.Methods: Moderate COVID‐19 patients (n = 34) at Lok Nayak Hospital, New Delhi, and COVID‐19 recovered patients (n = 15) from the mild disease who were considered for convalescent plasma (COPLA) donation at the Institute of Liver and Biliary Sciences, New Delhi and healthy individuals (n = 10), were recruited. We have assessed 21 plasma cytokines using cytokine bead array, performed proteomics on serum proteins, and analyzed immune cells using a detailed multicolor flow cytometry.Results: A significant increase in inflammatory markers such as macrophage inflammatory protein (MIP)1‐α, monocyte chemotactic protein‐1, macrophage migration inhibitory factor, vascular endothelial growth factor‐A, and Leptin was observed in the moderate patients. Nonsurvivors additionally showed increased interleukin (IL)‐6 levels. Consistently, the proteomics analysis showed the signatures of cytokine production and interferon‐γ response, and increased level of acute‐phase protein SAA1 in the serum of COVID‐19 patients. Despite the sustained expression of MIPs, the recovered COPLA donors showed a surge in MCSF and IL‐18 levels. Both the groups had increased CCR2, CX3CR1 positive monocytes, low CD8+ T cells, A proliferation‐inducing ligand, and B‐cell activating factor receptor+ B cells compared with healthy subjects.Conclusions: Patients who have recovered and considered for COPLA donations still have compromised immunity with sustained expression of inflammatory monocytes and activated T cells.


  • Open Access

    Survey based cross-sectional study to analyse the variation of practices at blood centres during COVID-19 pandemic in India

    by Abhishekh Basavarajegowda, Meenu Bajpai, Satyam Arora, Ashish Maheshwari, Seema Dua, Dibyajyoti Sahoo


  • Role of Plasma Exchange in Steroid Resistant Neuromyelitis Optica with Loss of Vision

    by Ashish Maheshwari, Dnyaneshwar Shridharrao Patale, Trupti Lokhande, Smita Chouhan, Sana Mariyam

    Neuromyelitis Optica (NMO) is a demyelinating inflammatory disorder of the spinal cord and optic nerve. As per American Society For Apheresis (ASFA) guidelines, Therapeutic Plasma Exchange (TPE) is considered as a second-line treatment in patients with weak or no response to steroid therapy. A patient of NMO presented to the tertiary care institute with a sudden loss of vision in the right eye. The patient was resistant to steroid treatment and improved significantly with TPE. Hence, TPE may be an effective treatment modality in steroid-resistant NMO with vision loss.

  • Open Access

    Poor nutritional status affecting blood donor deferral pattern at blood centre of North-East region of India

    by Ashish Maheshwari, Nawanita Kumari, Satya Prakash

    Background: Due to the stringent criteria for the selection of blood donors, donor deferral rate is increasing day by day, leading to a decrease in donor base for the blood bank. This study was done to analyze the incidence of deferral rate and deferral pattern to review the donor recruitment and retention policy and to highlight the role of nutrition improvement.Methods: A retrospective observational single-centre study was conducted in the department of transfusion medicine of North-East region of India from April 2018 to April 2019.Results: During the study period, a total of 3920 donations were made, and a total of 1992 donors were deferred. The overall deferral rate was 33.6% with male deferral rate was 29.4%, and the female deferral rate was 78.4%. Low haemoglobin and low weight contribute around 50% of total deferral.Conclusions: Analysis of donor deferral in a specific region is of utmost significance. Strategies to improve the health status of the population will help to increase donor pool in future, making easy availability of blood. The nutritional programme should be initiated for this group of deferred donors.